York Based Medical Devices Company Signs US Distribution Contract
Commercial interest in Dermapure� has significantly increased following Novitas, a Medicare Administrative Contractor covering US states representing 8.9 million Medicare beneficiaries, gave it a Local Coverage Determination (LCD) earlier this year.
This latest new contract is worth a minimum of $600k andcovers the next 12 months and builds on the increasing clinical awareness of the outstanding results being achieved in the US by Dermapure�. Tissue Regenix is also continuing to deploy its direct sales representatives as part of its �hybrid� distribution strategy of both direct and indirect sales representation.
Antony Odell, CEO of Tissue Regenix, commented: ""Our US team has done an outstanding job in achieving commercial traction for DermaPure� and signing this regional distribution agreement.This agreement validates the hard work put in since the launch of DermaPure� in June 2014, as well as the remarkable clinical results that we are seeing from the product.""
York-based Tissue Regenix Group, the regenerative medical devices company, has signed a new US distribution contract with TRX Wound Care Inc. for DermaPure� - a product used in the treatment of chronic and acute wounds.Tuesday, May 5, 2015"